Nephros, Inc. — Form 10-K summary
Reporting period: Fiscal year ended December 31, 2014. This filing reports full-year results, not standalone fourth-quarter results. Dollar amounts below are in millions unless stated otherwise. The 2013 comparative figures are restated.
Business context
Nephros develops and sells high-performance ultrafilters for dialysis, healthcare water treatment, military and commercial uses. It also has an FDA-cleared hemodiafiltration system that it was evaluating with dialysis providers. The company relies on outside manufacturers and distributors and had eight employees at year-end.
Financial results and liquidity
| Metric | 2014 | 2013 restated |
|---|---|---|
| Revenue | $1.748 | $1.740 |
| Product revenue | $0.914 | $1.029 |
| Licensing revenue | $0.834 | $0.711 |
| Gross profit / gross margin | $1.199 / 68.6% | $0.842 / 48.4% |
| Operating expenses | $3.868 | $4.159 |
| Operating loss | $(2.669) | $(3.317) |
| Net income (loss) | $(7.371) | $1.322 |
| Net cash used in operations | $(2.495) | $(3.583) |
| Cash at year-end | $1.284 | $0.579 |
| Working capital | $0.437 | $(2.511) |
Gross margin improved mainly because 2013 included substantial recall-related inventory reserves and other recall costs. Revenue was nearly flat: increased Bellco licensing revenue offset lower water-filter sales. R&D was $0.781 million and SG&A was $2.870 million in 2014, both down year over year. Interest expense rose to $0.483 million from $0.351 million.
The net result was significantly affected by noncash warrant remeasurement: the warrant liability’s fair value increased $4.277 million in 2014, versus a $5.020 million decrease recognized as income in 2013. The $7.386 million year-end warrant liability is not conventional borrowed debt. The $1.75 million August 2014 secured note, bearing 12% interest, was repaid in December; no senior secured note remained on the year-end balance sheet.
Stockholders’ deficit was $5.681 million at December 31, 2014, and accumulated deficit was $114.165 million. The company reported no positive operating cash flow in 2014 or 2013. December 2014 cash included proceeds from equity financing; management said available proceeds were expected to fund operations only into the second quarter of 2015, excluding future operating receipts.
Material changes and unusual items
- Restatement: The company reclassified certain 2007 warrants from equity to derivative liabilities because anti-dilution terms did not meet the accounting criteria for equity classification. It restated prior annual periods from 2009 through 2013 and 2013–2014 interim periods. The adjustment changed reported warrant liabilities, accumulated deficit and earnings, but did not affect previously reported revenue, operating expenses, operating income, cash flows or cash. Prior filings for affected periods are superseded and should no longer be relied upon.
- Financing and dilution: March and December 2014 rights offerings generated $5.1 million gross in total and issued approximately 12.1 million shares. The December offering alone raised $3.0 million gross; proceeds were used in part to repay the August Lambda note and associated amounts. Year-end shares outstanding were approximately 30.4 million.
- Product recall: The company recalled all production lots of its point-of-use hospital filters and requested removal of promotional materials for those and DSU filters in October 2013. It reported customer complaints involving high bacterial counts and stated that one death and one infection may have been associated with a filter failure; investigation was ongoing. Nephros requested recall termination in March 2014 and reported no further FDA communication as of the filing.
- Reporting controls: Management found disclosure controls and internal control over financial reporting ineffective at year-end due to a material weakness involving warrant accounting and limited finance resources. The company described remediation steps, including improved review of complex securities accounting.
Outlook, risks and contingencies
The auditor’s report and management’s disclosures raise substantial doubt about the company’s ability to continue as a going concern. Management said further financing, licensing or technology-sale proceeds may be needed; it warned that unavailable or insufficient capital could force reductions in activities or cessation of operations. The filing provides no formal financial guidance.
Commercial milestones included FDA 510(k) clearance in October 2014 for DSU-H and SSU-H hospital filters, a Canadian license for the SSU, and distributor arrangements for dialysis products. DaVita’s evaluation of the HDF system required additional validation; the submitted data remained under review at the filing date. The Army cancelled an earlier IWTD solicitation and later requested information; Nephros supplied 50 devices for testing in January 2015. These developments had not established broad commercial adoption.
Key risks include limited cash runway and recurring losses; reliance on additional financing; product safety, recall, regulatory and liability exposure; uncertain market acceptance and commercialization; customer concentration (three customers represented 78% of 2014 revenue); dependence on third-party manufacturing and suppliers; and dilution and limited trading liquidity. Medica purchase commitments and future minimum amounts were also relevant: the 2015 annual minimum had not been finalized. The filing reported no pending legal proceedings.
Important facts for investors to verify
- Current cash runway, subsequent financing, and whether the company has obtained funding beyond the stated second-quarter 2015 horizon.
- Progress on remediating the material weakness and the accuracy of restated financial information, including the valuation assumptions for the Level 3 warrant liability.
- FDA status and any claims, investigations, or liabilities related to the hospital-filter recall and reported possible adverse events.
- Commercial validation, adoption and revenue potential for HDF, hospital filters and military water purifiers, including the status of DaVita and Army evaluations.
- Customer concentration, Medica purchase obligations, and the terms and potential dilution of outstanding warrants and equity awards.